Gilead Sciences, Inc.
GILD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $138 | $138 | $140 | $115 |
| - Cash | $9 | $5 | $8 | $10 |
| + Debt | $3 | $25 | $25 | $27 |
| Enterprise Value | $131 | $158 | $157 | $133 |
| Revenue | $8 | $7 | $7 | $8 |
| % Growth | 9.7% | 6.2% | -11.9% | – |
| Gross Profit | $6 | $6 | $5 | $6 |
| % Margin | 79.8% | 78.8% | 76.9% | 79.1% |
| EBITDA | $5 | $3 | $3 | $3 |
| % Margin | 59% | 47.6% | 39.1% | 41.1% |
| Net Income | $3 | $2 | $1 | $2 |
| % Margin | 39.3% | 27.7% | 19.7% | 23.6% |
| EPS Diluted | 2.43 | 1.56 | 1.04 | 1.42 |
| % Growth | 55.8% | 50% | -26.8% | – |
| Operating Cash Flow | $4 | $1 | $2 | $3 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $4 | $1 | $2 | $3 |